180 related articles for article (PubMed ID: 34342494)
21. Navigating the treatment landscape in multiple myeloma: which combinations to use and when?
Goldschmidt H; Ashcroft J; Szabo Z; Garderet L
Ann Hematol; 2019 Jan; 98(1):1-18. PubMed ID: 30470875
[TBL] [Abstract][Full Text] [Related]
22. Initial treatment of transplant-ineligible patients in multiple myeloma.
Mateos MV; Leleu X; Palumbo A; San Miguel JF
Expert Rev Hematol; 2014 Feb; 7(1):67-77. PubMed ID: 24308500
[TBL] [Abstract][Full Text] [Related]
23. Adoption of triplet therapy and clinical outcomes in routine practice among newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant in the USA.
Hari P; Blazer M; Raju A; Farrelly E; Labotka R; Skacel T; Romanus D
Expert Rev Hematol; 2019 Jan; 12(1):71-79. PubMed ID: 30513016
[TBL] [Abstract][Full Text] [Related]
24. Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients.
Djebbari F; Sharpley FA; McLain-Smith S; Vallance G; Eyre TA; Kothari J; Moore S; Ramasamy K
PLoS One; 2020; 15(2):e0229469. PubMed ID: 32084254
[TBL] [Abstract][Full Text] [Related]
25. Impact of Socioeconomic Characteristics and Comorbidities on Therapy Initiation and Outcomes of Newly Diagnosed Multiple Myeloma: Real-World Data From a Resource-Constrained Setting.
Vargas-Serafin C; Acosta-Medina AA; Ordonez-Gonzalez I; Martínez-Baños D; Bourlon C
Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):182-187. PubMed ID: 33414064
[TBL] [Abstract][Full Text] [Related]
26. Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study.
Li J; Bao L; Xia Z; Wang S; Zhou X; Ding K; Zhang W; Yang W; Li B; Fu C; Chen B; Hua L; Wang L; Luo J; Yang Y; Xu T; Wang W; Huang Y; Wu G; Liu P
Ann Hematol; 2020 Nov; 99(11):2589-2598. PubMed ID: 32892275
[TBL] [Abstract][Full Text] [Related]
27. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
Korde N; Roschewski M; Zingone A; Kwok M; Manasanch EE; Bhutani M; Tageja N; Kazandjian D; Mailankody S; Wu P; Morrison C; Costello R; Zhang Y; Burton D; Mulquin M; Zuchlinski D; Lamping L; Carpenter A; Wall Y; Carter G; Cunningham SC; Gounden V; Sissung TM; Peer C; Maric I; Calvo KR; Braylan R; Yuan C; Stetler-Stevenson M; Arthur DC; Kong KA; Weng L; Faham M; Lindenberg L; Kurdziel K; Choyke P; Steinberg SM; Figg W; Landgren O
JAMA Oncol; 2015 Sep; 1(6):746-54. PubMed ID: 26181891
[TBL] [Abstract][Full Text] [Related]
28. Evolution of Treatment Paradigms in Newly Diagnosed Multiple Myeloma.
Elnair RA; Holstein SA
Drugs; 2021 May; 81(7):825-840. PubMed ID: 33871818
[TBL] [Abstract][Full Text] [Related]
29. Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials.
Bhutani M; Zhang Q; Friend R; Voorhees PM; Druhan LJ; Barlogie B; Sonneveld P; Morgan GJ; Symanowski JT; Avalos BR; Copelan EA; Usmani SZ
Lancet Haematol; 2017 Sep; 4(9):e443-e451. PubMed ID: 28863804
[TBL] [Abstract][Full Text] [Related]
30. Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against.
Richardson PG; Holstein SA; Schlossman RL; Anderson KC; Attal M; McCarthy PL
Expert Opin Pharmacother; 2017 Dec; 18(18):1975-1985. PubMed ID: 29172855
[TBL] [Abstract][Full Text] [Related]
31. Incidence of thromboembolism and associated factors in multiple myeloma patients treated with immunomodulatory drugs: a retrospective analysis in Belo Horizonte, Brazil.
da Costa IHF; de Pádua CAM; de Miranda Drummond PL; Silveira LP; Malta JS; Dos Santos RMM; Reis AMM
Support Care Cancer; 2023 Dec; 32(1):35. PubMed ID: 38103099
[TBL] [Abstract][Full Text] [Related]
32. Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing.
D'Agostino M; Zaccaria GM; Ziccheddu B; Rustad EH; Genuardi E; Capra A; Oliva S; Auclair D; Yesil J; Colucci P; Keats JJ; Gambella M; Bringhen S; Larocca A; Boccadoro M; Bolli N; Maura F; Gay F
Clin Cancer Res; 2020 Sep; 26(18):4832-4841. PubMed ID: 32616499
[TBL] [Abstract][Full Text] [Related]
33. Novel therapies for multiple myeloma.
Wallington-Beddoe CT; Pitson SM
Aging (Albany NY); 2017 Aug; 9(8):1857-1858. PubMed ID: 28854147
[No Abstract] [Full Text] [Related]
34. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
35. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
Kumar SK; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R; Kaufman JL; Berg D; Liao E; Di Bacco A; Estevam J; Gupta N; Hui AM; Rajkumar V; Richardson PG
Lancet Oncol; 2014 Dec; 15(13):1503-1512. PubMed ID: 25456369
[TBL] [Abstract][Full Text] [Related]
36. Real-world study on adoption of standard-of-care for transplant-eligible newly diagnosed multiple myeloma patients between 2017 and 2020/2021 across France, Germany, Spain, and Italy.
Weisel K; Wadlund AO; Gungor G; Dergarabetian E; Pacheco C; Masurkar N; Rodriguez-Otero P
Eur J Haematol; 2022 Oct; 109(4):388-397. PubMed ID: 35775385
[TBL] [Abstract][Full Text] [Related]
37. Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance.
Kumar SK; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R; Kaufman JL; Berg D; Liao E; Rajkumar SV; Richardson PG
Leukemia; 2019 Jul; 33(7):1736-1746. PubMed ID: 30696949
[TBL] [Abstract][Full Text] [Related]
38. Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib.
Manda S; Yimer HA; Noga SJ; Girnius S; Yasenchak CA; Charu V; Lyons R; Aiello J; Bogard K; Ferrari RH; Cherepanov D; Demers B; Lu V; Whidden P; Kambhampati S; Birhiray RE; Jhangiani HS; Boccia R; Rifkin RM
Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e910-e925. PubMed ID: 32912820
[TBL] [Abstract][Full Text] [Related]
39. Proteasome inhibitors for multiple myeloma.
Okazuka K; Ishida T
Jpn J Clin Oncol; 2018 Sep; 48(9):785-793. PubMed ID: 30102324
[TBL] [Abstract][Full Text] [Related]
40. Survival and treatment patterns of patients with relapsed or refractory multiple myeloma in France - a cohort study using the French National Healthcare database (SNDS).
Touzeau C; Quignot N; Meng J; Jiang H; Khachatryan A; Singh M; Taieb V; Chauny JV; Désaméricq G
Ann Hematol; 2021 Jul; 100(7):1825-1836. PubMed ID: 33884454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
